Global Antibody Drug Conjugates Market Poised to Reach $19.8 Billion by 2028, Fueled by Increasing Cancer Prevalence and Clinical Advancements
26 oct. 2023 07h33 HE
|
Research and Markets
Dublin, Oct. 26, 2023 (GLOBE NEWSWIRE) -- The "Global Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type...
Elucida Oncology Presents Encouraging Clinical Data from Phase 1/2 Study of ELU001 in Solid Tumors Overexpressing Folate Receptor Alpha at ESMO Congress 2023
23 oct. 2023 08h00 HE
|
Elucida Oncology, Inc
Anti-tumor activity observed across all levels of folate receptor alpha (“FRα”) expression89% of patients with cancers expressing FRα showed stable disease or a partial response following treatment...
ADC (Antibody Drug Conjugates) Markets, 2035
17 oct. 2023 07h38 HE
|
Research and Markets
Dublin, Oct. 17, 2023 (GLOBE NEWSWIRE) -- The "ADC Technology Market: Focus on ADC Linker and ADC Conjugation Technologies (2nd Edition) - Distribution by Generation of ADC Technology, Type of...
Antibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 – Exclusive Study by The Insight Partners
09 oct. 2023 08h04 HE
|
The Insight Partners
Pune, India, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Antibody drug conjugates (ADC) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody (mAbs) covalently...
Antibody Drug Conjugates Market to increase by USD 34.7 Billion by 2032 || North America led with a 40% revenue share in 2022
25 sept. 2023 09h23 HE
|
Market.Us
New York, Sept. 25, 2023 (GLOBE NEWSWIRE) -- According to a recent report by Market.us, the Global Antibody Drug Conjugates Market size is expected to be worth around USD 34.7 Billion by 2032 from...
Elucida Oncology Appoints Ramzi Benamar as Chief Financial Officer
24 août 2023 11h00 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that...
Antibody Drug Conjugate (ADC) Markets, 2035
24 août 2023 06h33 HE
|
Research and Markets
Dublin, Aug. 24, 2023 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugate Market (7th Edition): Distribution by Target Disease Indication, Therapeutic Area, Linker, Payload, Target Antigens And Key...
Global Antibody Drug Conjugate (ADC) Forecast to 2028 - Next-Generation ADCs Spurring Growth Opportunities
22 août 2023 08h03 HE
|
Research and Markets
Dublin, Aug. 22, 2023 (GLOBE NEWSWIRE) -- The "Global Antibody Drug Conjugate (ADC) Growth Opportunities, Forecast to 2028" report has been added to ResearchAndMarkets.com's offering. The report...
Elucida Oncology Announces First Patient Dosed with ELU001 in Expansion Cohort of its Phase 1/2 Clinical Trial
20 juil. 2023 11h45 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company developing the next frontier in targeted cancer therapy, announced today that the...
Global Cancer Antibody Drug Conjugates Market Outlook to 2029: Size, Drug Sales, Drug Dosage, Price, & Clinical Trials
16 juin 2023 06h28 HE
|
Research and Markets
Dublin, June 16, 2023 (GLOBE NEWSWIRE) -- The "Global Cancer Antibody Drug Conjugates Market Outlook 2029" report has been added to ResearchAndMarkets.com's offering.Global Cancer Antibody Drug...